Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Dabrafenib is a kinase inhibitor developed by Novartis Pharmaceuticals. It was f···【more】
Release date：2026-03-19Recommended：43
Sparsentan, developed by Travere Therapeutics, is a dual receptor antagonist tha···【more】
Release date：2026-03-18Recommended：54
Sparsentan, developed by Travere Therapeutics, is an endothelin and angiotensin ···【more】
Release date：2026-03-18Recommended：57
During treatment with Sparsentan, regular monitoring is required. Follow-up shou···【more】
Release date：2026-03-18Recommended：54
Sparsentan is the first dual pathway blocker. Its usage and dosage should be det···【more】
Release date：2026-03-18Recommended：49
Elacestrant, an estrogen receptor antagonist developed by the Italian company Me···【more】
Release date：2026-03-16Recommended：52
Elacestrant, while exerting its therapeutic effects, can also cause some side ef···【more】
Release date：2026-03-16Recommended：42
Regarding the dosage of elacestrant, in addition to the recommended dose, approp···【more】
Release date：2026-03-16Recommended：51
Elacestrant is an estrogen receptor antagonist developed by the Italian company ···【more】
Release date：2026-03-16Recommended：55
Capmatinib is a targeted therapy for non-small cell lung cancer with MET exon 14···【more】
Release date：2026-03-13Recommended：49
Capmatinib (Tabrecta) is a highly selective MET receptor tyrosine kinase inhibit···【more】
Release date：2026-03-13Recommended：84
Ixazomib, as a novel targeted therapy, blocks the growth and proliferation of tu···【more】
Release date：2026-03-13Recommended：53
